美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Propanc Biopharma, Inc.

1.58

0.0000

盘后：1.590.0100+0.63%19:37 EDT

成交量：7.82万

成交额：12.25万

市值：2,023.47万

市盈率：-0.11

高：1.60

开：1.54

低：1.54

收：1.58

52周最高：24.00

52周最低：0.0002

股本：1,280.67万

流通股本：340.45万

量比：0.22

换手率：2.30%

股息：- -

股息率：- -

每股收益(TTM):-14.8490

每股收益(LYR):-14.8490

净资产收益率：-1163.67%

总资产收益率：-363.36%

市净率：1.46

市盈率(LYR):-0.11

数据加载中...

总览公司新闻公告

公司资料

公司名字：

Propanc Biopharma, Inc.

交易所：

NASDAQ

成立时间：

2007

员工人数：

2

公司地址：

302, 6 Butler Street,Camberwell,Victoria,Australia

官网：

http://www.propanc.com

邮编：

3124

电话：

传真：

61 3 9882 9969

简介：

Propanc Biopharma, Inc.最初于2007年10月15日在澳大利亚维多利亚州墨尔本成立。2010年11月23日，该公司在特拉华州重新注册并重新注册。他们是一家发展阶段的医疗保健公司，目前专注于为患有胰腺癌、卵巢癌和癌症的患者开发新的癌症治疗方法。利用他们的科学和肿瘤学顾问，他们开发了一种合理的抗癌化合物复合配方，这些化合物共同发挥多种作用，旨在控制或防止肿瘤在体内复发和扩散。他们的主要候选产品PRP是他们新配方的变体，涉及酶原，即酶的无活性前体。

董事

名称

职位

James Nathanielsz

Chief Executive Officer and Director

Annie VanBroekhoven

Independent Director

Josef Zelinger

Independent Director

Joseph Himy

Independent Director

Julian Kenyon

Director

股东

名称

职位

James Nathanielsz

Chief Executive Officer and Director

Jeannine Zimmerman

Chief Financial Officer

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/PPCB/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PPCB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":1.58,"timestamp":1760731200000,"preClose":1.58,"halted":0,"volume":78241,"hourTrading":{"tag":"盘后","latestPrice":1.59,"preClose":1.58,"latestTime":"19:37 EDT","volume":8936,"amount":14072.97,"timestamp":1760744254130},"delay":0,"floatShares":3404500,"shares":12806747,"eps":-14.848963,"marketStatus":"休市中","change":0,"latestTime":"10-17 16:00:00 EDT","open":1.54,"high":1.6,"low":1.54,"amount":122490.15842949999,"amplitude":0.037975,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-14.848963,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":7,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":1.58,"preHourTrading":{"tag":"盘前","latestPrice":1.5599,"preClose":1.58,"latestTime":"09:25 EDT","volume":1235,"amount":1953.926104,"timestamp":1760707541221},"postHourTrading":{"tag":"盘后","latestPrice":1.59,"preClose":1.58,"latestTime":"19:37 EDT","volume":8936,"amount":14072.97,"timestamp":1760744254130},"volumeRatio":0.21689715181885963},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","floatShares":3404500,"roa":"-363.36%","roe":"-1163.67%","lyrEps":-14.848963,"volumeRatio":0.21689715181885963,"shares":12806747,"dividePrice":0,"high":1.6,"amplitude":0.037975,"preClose":1.58,"low":1.54,"week52Low":0.0002,"pbRate":"1.46","week52High":24,"institutionHeld":0,"latestPrice":1.58,"eps":-14.848963,"divideRate":0,"volume":78241,"delay":0,"ttmEps":-14.848963,"open":1.54,"prevYearClose":0.0002,"prevWeekClose":1.73,"prevMonthClose":1.7,"prevQuarterClose":1.7,"fiveDayClose":1.73,"twentyDayClose":2.16,"sixtyDayClose":4.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPCB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-01-29","symbol":"PPCB","defaultRemindTime":1738161000000,"type":"split","dateTimestamp":1738126800000,"forFactor":60000,"toFactor":1,"ratio":60000},{"market":"US","date":"2023-05-23","symbol":"PPCB","defaultRemindTime":1684848600000,"type":"split","dateTimestamp":1684814400000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2020-11-19","symbol":"PPCB","defaultRemindTime":1605796200000,"type":"split","dateTimestamp":1605762000000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2019-06-24","symbol":"PPCB","type":"split","dateTimestamp":1561348800000,"forFactor":500,"toFactor":1,"ratio":500}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPCB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPCB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PPCB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PPCB","date":"2025-10-17","current":-0.106405,"percent":0.914894,"low":-1.336323,"twenty":-0.669984,"median":-0.449583,"eighty":-0.385572,"high":-0.048332,"avg":-0.500614,"sd":0.235565,"marketCap":20234660},"quantilePoints":[{"date":"2025-04-04","current":-0.050633,"twenty":-0.050633,"median":-0.050633,"eighty":-0.050633,"marketCap":84546},{"date":"2025-04-07","current":-0.048332,"twenty":-0.050633,"median":-0.050633,"eighty":-0.049713,"marketCap":80703},{"date":"2025-08-22","current":-0.938461,"twenty":-0.969897,"median":-0.655598,"eighty":-0.050633,"marketCap":51812834},{"date":"2025-08-29","current":-0.721182,"twenty":-0.884372,"median":-0.710781,"eighty":-0.050633,"marketCap":39816759},{"date":"2025-09-05","current":-0.457673,"twenty":-0.820575,"median":-0.688821,"eighty":-0.213449,"marketCap":25268328},{"date":"2025-09-12","current":-0.457673,"twenty":-0.778969,"median":-0.631034,"eighty":-0.41283,"marketCap":25268328},{"date":"2025-09-19","current":-0.506214,"twenty":-0.755854,"median":-0.517772,"eighty":-0.439644,"marketCap":27948302},{"date":"2025-09-26","current":-0.418378,"twenty":-0.712861,"median":-0.510837,"eighty":-0.435021,"marketCap":23098825},{"date":"2025-10-03","current":-0.399917,"twenty":-0.699454,"median":-0.498124,"eighty":-0.407301,"marketCap":23564414},{"date":"2025-10-10","current":-0.408611,"twenty":-0.69067,"median":-0.457673,"eighty":-0.403395,"marketCap":24076684},{"date":"2025-10-17","current":-0.343407,"twenty":-0.669984,"median":-0.449583,"eighty":-0.385572,"marketCap":20234660}],"updateTime":1760816574685},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":134729532,"yearFounded":2007,"employeeNum":2,"address":"302, 6 Butler Street,Camberwell,Victoria,Australia","zipCode":"3124","officePhone":"61 3 9882 0780","officeFax":"61 3 9882 9969"},"stockCompanyDetail":{"websiteUrl":"http://www.propanc.com","stockEarnings":[{"period":"1week","weight":-0.0867},{"period":"1month","weight":-0.2851},{"period":"3month","weight":-0.6489},{"period":"6month","weight":-0.8025},{"period":"1year","weight":5265.6667},{"period":"ytd","weight":7899}],"compareEarnings":[{"period":"1week","weight":0.0174},{"period":"1month","weight":0.0079},{"period":"3month","weight":0.0587},{"period":"6month","weight":0.2621},{"period":"1year","weight":0.1409},{"period":"ytd","weight":0.1336}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Propanc Biopharma, Inc.最初于2007年10月15日在澳大利亚维多利亚州墨尔本成立。2010年11月23日，该公司在特拉华州重新注册并重新注册。他们是一家发展阶段的医疗保健公司，目前专注于为患有胰腺癌、卵巢癌和癌症的患者开发新的癌症治疗方法。利用他们的科学和肿瘤学顾问，他们开发了一种合理的抗癌化合物复合配方，这些化合物共同发挥多种作用，旨在控制或防止肿瘤在体内复发和扩散。他们的主要候选产品PRP是他们新配方的变体，涉及酶原，即酶的无活性前体。","exchange":"NASDAQ","name":"Propanc Biopharma, Inc.","nameEN":"Propanc Biopharma, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PPCB\",market:\"US\",,,undefined,":{"directors":[{"name":"James Nathanielsz","position":"Chief Executive Officer and Director"},{"name":"Annie VanBroekhoven","position":"Independent Director"},{"name":"Josef Zelinger","position":"Independent Director"},{"name":"Joseph Himy","position":"Independent Director"},{"name":"Julian Kenyon","position":"Director"}],"executives":[{"name":"James Nathanielsz","position":"Chief Executive Officer and Director"},{"name":"Jeannine Zimmerman","position":"Chief Financial Officer"}]}}}